Skip to main content
Glama

Related Servers

Alternatives to anvisa-mcp

No user-submitted related servers found.

    Related Servers

    • A
      license
      A
      quality
      D
      maintenance
      Enables LLMs to search FDA drug labels and adverse event data via the OpenFDA API, supporting natural language queries for drug safety information.
      2
      MIT
    • A
      license
      Not graded
      quality
      C
      maintenance
      MCP server for querying the official ANVISA electronic drug bulletin from a trusted source. It provides a single read-only tool for consulting drug information through natural language in any MCP-compatible client.
      MIT
    • A
      license
      A
      quality
      D
      maintenance
      Provides LLM-optimized access to FDA data through the OpenFDA API and direct regulatory decision document retrieval, covering all 21 OpenFDA endpoints plus 510(k) summaries, De Novo decisions, and PMA approvals.
      4
      1
      MIT
    • A
      license
      Not graded
      quality
      F
      maintenance
      Provides comprehensive pharmaceutical intelligence by integrating real-time openFDA data with locally-cached Orange Book and Purple Book databases. It enables users to analyze drug safety, patents, generic equivalents, biosimilars, and regulatory information through natural language queries.
      3
      MIT

    TDQS

    A4.3/5.0

    Scored across 2 tools

    Disambiguation5/5

    The two tools operate in completely separate domains: one retrieves recent Class III/IV medical devices with AI classification, the other queries drug registration status. There is no overlap or ambiguity between them.

    Naming Consistency5/5

    Both tool names follow the same verb_noun pattern in Portuguese: buscar_samd_recentes and consultar_status_medicamento. The naming is clean, descriptive, and consistent.

    Tool Count3/5

    With only two tools, the server feels thin for the broad regulatory scope of Anvisa. The count is borderline acceptable because each tool covers a distinct product category, but it leaves many common regulatory queries unaddressed.

    Completeness2/5

    The device tool only covers recent SaMD registrations with a heuristic AI filter, and the drug tool only checks registration status. There are significant gaps such as searching devices by name/number, retrieving full regulatory details, or covering other Anvisa-regulated product types.

    Maintenance

    ActivityMaintained
    ResponsivenessNo issues